Stefan Robert Kappeler

Exyte Management GmbH
Technology Manager Life Sciences
Stefan R. Kappeler works at Exyte as Senior Director Biopharma & Regulatory. He received his PhD in molecular biotechnology from the Swiss Federal Institute of Technology in Zurich and has over 30 years of experience in life sciences. During this time, he has completed a variety of projects in research, clinical development, early and late process development, technology transfer, upstream and downstream biological drug manufacturing, quality control and assurance, facility design, engineering, commissioning and qualification. His main interests are in advanced plant design, trends in manufacturing methods and the implementation of advanced technologies in pharmaceutical engineering.

Related Articles

Effect of Industry 4.0 enablers on the product life cycle.
Features
Data Science for Pharma 4.0™: Drug Development, & Production—Part 2

This second of a two-part series explores digital transformation and digitalization in the biopharmaceutical industry with information about how data science enables digitalization along the product life cycle. (Part 1 was published in the March-April 2021 issue of Pharmaceutical Engineering.1

  • 1Herwig, C., et al. “Data Science for Pharma 4.0™, Drug Development, and Production—Part...
Effect of Indutry 4.0 enablers on the manufacturing process chain. Upper arrow: Conventional approach. Lower arrow: Perceived extended process chain using IIoT enablers.
Features
Data Science for Pharma 4.0™, Drug Development, & Production—Part 1

Digital transformation and digitalization are on the agenda for all organizations in the biopharmaceutical industry. But what are the main enablers of intelligent manufacturing? We hypothesize that data science–derived manufacturing process and product understanding is the main driver of digitalization in the bioprocessing industry for biologics manufacturing. In this article, the first of a...